A
Alessandra Iurlo
Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Publications - 318
Citations - 5258
Alessandra Iurlo is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 31, co-authored 255 publications receiving 3769 citations. Previous affiliations of Alessandra Iurlo include University of Milan.
Papers
More filters
Journal ArticleDOI
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli,Guido Finazzi,Giorgina Specchia,Rossella R. Cacciola,Riccardo Cavazzina,Daniela Cilloni,Valerio De Stefano,Elena Maria Elli,Alessandra Iurlo,Roberto Latagliata,Francesca Lunghi,Monia Lunghi,Rosa Maria Marfisi,Pellegrino Musto,Arianna Masciulli,Caterina Musolino,Nicola Cascavilla,Giovanni Quarta,Maria Luigia Randi,Davide Rapezzi,Marco Ruggeri,Elisa Rumi,Anna Rita Scortechini,Simone Santini,Marco Scarano,Sergio Siragusa,Antonio Spadea,Alessia Tieghi,Emanuele Angelucci,Giuseppe Visani,Alessandro M. Vannucchi,Tiziano Barbui +31 more
TL;DR: In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with an intended target of 45 to 50%.
Journal ArticleDOI
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
Silvia Mori,Elisabetta Vagge,Philipp le Coutre,Elisabetta Abruzzese,Bruno Martino,Ester Pungolino,Chiara Elena,Ivana Pierri,Sarit Assouline,Anna D'Emilio,Antonella Gozzini,Pilar Giraldo,Fabio Stagno,Alessandra Iurlo,Michela Luciani,Giulia De Riso,Sara Redaelli,Dong-Wook Kim,Alessandra Pirola,Caterina Mezzatesta,Anna Petroccione,Agnese Lodolo D'Oria,Patrizia Crivori,Rocco Piazza,Carlo Gambacorti-Passerini +24 more
TL;DR: The ISAV study is a multicentre trial aimed at validating dPCR to predict relapses after imatinib discontinuation in CML patients with undetectable Q‐RT‐PCR, finding an inverse relationship between patients age and risk of relapse was evident.
Journal ArticleDOI
Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the SEC23B gene.
Paola Bianchi,Elisa Fermo,Cristina Vercellati,Carla Boschetti,Wilma Barcellini,Alessandra Iurlo,Anna Paola Marcello,Pier Giorgio Righetti,Alberto Zanella +8 more
TL;DR: Abnormalities in this gene are likely to disturb endoplasmic reticulum (ER)‐to‐Golgi trafficking, affecting different glycosylation pathways and ultimately accounting for the cellular phenotype observed in CDAII.
Journal ArticleDOI
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
F. Efficace,Michele Baccarani,Giovanni Rosti,Francesco Cottone,Fausto Castagnetti,Massimo Breccia,Giuliana Alimena,Alessandra Iurlo,Antonella Russo Rossi,Simonetta Pardini,Filippo Gherlinzoni,Marzia Salvucci,Mario Tiribelli,Marco Vignetti,Franco Mandelli +14 more
TL;DR: This study suggests that a higher level of social support, satisfaction with information received and concomitant drug burden are the main factors associated with greater adherence to long-term imatinib therapy.
Journal ArticleDOI
The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.
Umberto Gianelli,Claudia Vener,Anna Bossi,Ivan Cortinovis,Alessandra Iurlo,Nicola Stefano Fracchiolla,Federica Savi,Alessia Moro,Federica Irene Grifoni,Chiara De Philippis,Tommaso Radice,Silvano Bosari,Giorgio Lambertenghi Deliliers,Agostino Cortelezzi +13 more
TL;DR: Analysis of the overall survival curves documented that patients classified as having the most favourable rate with both prognostic scores survive longer than those with only one favourable score, while better prognostication can be achieved in primary myelofibrosis patients when both systems are used together.